The Paradox of Charismatic Leadership: A Critical Analysis of Elizabeth Holmes and the Rise and Fall of Theranos

Martin Munyao Muinde

 

Abstract

This case study examines the leadership trajectory of Elizabeth Holmes, founder and former CEO of Theranos, through multiple theoretical frameworks including transformational leadership theory, ethical leadership models, and dark triad personality constructs. Through analysis of primary documentation, court records, journalistic accounts, and secondary literature, this research investigates how initially lauded leadership qualities transformed into destructive patterns that ultimately resulted in organizational failure and criminal conviction. The analysis reveals how Holmes embodied paradoxical leadership elements: visionary communication that inspired significant investment while simultaneously concealing fundamental technological limitations; transformational qualities that motivated employee commitment while fostering a culture of fear and information control; and image management strategies that initially built legitimacy but ultimately could not sustain scrutiny when confronted with empirical challenges. This case illuminates critical lessons regarding the dangers of unchecked charismatic authority, the importance of governance oversight, and the ethical responsibilities of leadership in innovation-driven contexts. The findings contribute to scholarly understanding of leadership failure trajectories and provide insights for investors, board members, and organizational stakeholders regarding early warning signs of leadership pathologies, particularly within high-growth technological ventures where traditional performance metrics may be temporarily suspended during developmental phases.

Introduction: The Phenomenon of Elizabeth Holmes

The meteoric rise and catastrophic fall of Elizabeth Holmes and her company Theranos represents one of the most significant and instructive leadership case studies of the early twenty-first century. Holmes, who founded Theranos in 2003 at the age of 19 after dropping out of Stanford University, created a compelling narrative around revolutionary blood-testing technology that promised to fundamentally transform diagnostic medicine through miniaturization, automation, and dramatically reduced costs. By 2014, Theranos had achieved a valuation of approximately $9 billion, making Holmes, with her 50% ownership stake, the youngest self-made female billionaire in history (Carreyrou, 2018). Her leadership narrative resonated particularly powerfully within Silicon Valley’s entrepreneurial ecosystem and the broader cultural context, which increasingly celebrated disruptive innovation and technological solutionism.

However, by 2018, following investigative journalism that revealed fundamental technological failures, regulatory interventions, and mounting legal challenges, Theranos had dissolved and its assets liquidated. In January 2022, Holmes was convicted on four counts of fraud for deceiving investors about Theranos’s technological capabilities and business operations. This extraordinary reversal of fortune raises profound questions about the nature of leadership, organizational ethics, governance mechanisms, and the cultural contexts that enable such dramatic failures of oversight.

This case study applies multiple theoretical frameworks to analyze Holmes’s leadership, examining how characteristics initially perceived as strengths – visionary communication, unwavering confidence, transformational inspiration, and strategic image management – ultimately contributed to catastrophic leadership failure. By understanding the specific mechanisms through which these leadership pathologies developed and persisted despite mounting contradictory evidence, this analysis contributes to both scholarly understanding of leadership dynamics and practical knowledge for preventing similar organizational failures.

Methodological Framework

This case study employs a qualitative analytical approach drawing upon multiple data sources to construct a comprehensive examination of Holmes’s leadership. Primary sources include court documents from the United States v. Elizabeth Holmes criminal trial, Theranos corporate communications, contemporaneous media interviews, and Holmes’s public presentations. Secondary sources include investigative journalism (particularly John Carreyrou’s extensive reporting in The Wall Street Journal and subsequent book “Bad Blood”), academic analyses, regulatory documents from the Centers for Medicare & Medicaid Services and the Securities and Exchange Commission, and testimonial accounts from former employees, investors, and board members.

The analytical framework integrates multiple theoretical perspectives to evaluate Holmes’s leadership:

1. Transformational leadership theory (Bass & Riggio, 2006), examining idealized influence, inspirational motivation, intellectual stimulation, and individualized consideration dimensions.

2. Charismatic leadership dynamics (Conger & Kanungo, 1998), analyzing vision articulation, personal risk, environmental sensitivity, unconventional behavior, and follower effects.

3. Dark triad personality constructs (Paulhus & Williams, 2002), considering narcissistic, Machiavellian, and psychopathic characteristics in leadership behavior.

4. Ethical leadership models (Brown & Treviño, 2006), evaluating normative appropriateness of conduct and the promotion of such conduct among followers.

5. Impression management theory (Goffman, 1959; Leary & Kowalski, 1990), examining strategic self-presentation techniques to cultivate specific perceptions.

This multi-theoretical approach enables a nuanced analysis of how Holmes’s leadership qualities manifested across different organizational stages, stakeholder relationships, and environmental contexts. The case study organizes findings chronologically while simultaneously developing thematic connections to theoretical constructs, allowing for identification of evolving leadership patterns and critical inflection points in organizational trajectory.

The Construction of Charismatic Authority: Vision, Identity, and Narrative

Elizabeth Holmes’s leadership effectiveness during Theranos’s ascendancy phase derived substantially from her capacity to construct and project a compelling charismatic authority. This charismatic authority rested upon three interrelated elements: an ambitious technological vision, a carefully crafted leadership identity, and a persuasive narrative that connected the enterprise to broader societal transformation.

Holmes articulated a revolutionary vision centered on democratizing healthcare through radical innovation in blood diagnostics. She repeatedly emphasized how Theranos’s purported technological breakthroughs would enable comprehensive testing from microscopic blood samples, facilitating early disease detection, reducing patient discomfort, decreasing healthcare costs, and ultimately saving lives. This vision effectively synthesized technological innovation with humanitarian purpose, creating what Weber (1947) characterized as a form of “value-rational authority” that legitimized her leadership through association with transcendent social good rather than purely economic objectives.

The construction of Holmes’s leadership identity incorporated both visual and behavioral elements designed to enhance charismatic impact. Most visibly, Holmes adopted a distinctive personal aesthetic, wearing exclusively black turtleneck sweaters explicitly modeled after Apple founder Steve Jobs, whom she frequently cited as an inspiration. This deliberate visual association with one of technology’s most celebrated visionaries served to transfer legitimacy through symbolic connection. Further, Holmes cultivated behavioral distinctiveness through her unusually deep voice (later revealed to be artificially lowered), direct speaking style, minimal blinking during conversations, and unwavering confidence when discussing technological capabilities. These behaviors created a distinctive leadership presence that was frequently described by investors and media as “mesmerizing” and “hypnotic” (Carreyrou, 2018).

Holmes deployed a carefully constructed narrative that positioned Theranos within broader societal narratives about technological disruption, healthcare transformation, and gender dynamics in entrepreneurship. Her personal story—the Stanford dropout who pursued a revolutionary vision—deliberately evoked comparisons to Silicon Valley archetypes like Jobs, Gates, and Zuckerberg. However, Holmes distinguished her narrative by emphasizing how Theranos’s technology would specifically benefit vulnerable populations, including those with chronic diseases, economic disadvantages, or geographic barriers to healthcare access. This narrative framing elevated the enterprise from mere commercial venture to humanitarian mission, enhancing both emotional resonance and moral legitimacy.

The effectiveness of Holmes’s charismatic authority construction is evidenced by her ability to attract extraordinary resources despite limited technological validation. By 2014, Theranos had raised approximately $700 million from investors including prominent venture capital firms and high-profile individuals such as Rupert Murdoch, Betsy DeVos, and the Walton family. More remarkably, Holmes recruited a board of directors featuring former Secretaries of State George Shultz and Henry Kissinger, former Defense Secretary William Perry, former Senators Sam Nunn and Bill Frist, and other distinguished public figures with limited healthcare technology expertise but significant reputational capital (Carreyrou, 2018). These recruitment successes demonstrate how effectively Holmes’s charismatic leadership projected legitimacy that compensated for the absence of traditional technological validation markers such as peer-reviewed publications or independent verification.

Organizational Culture and Control Mechanisms

The internal manifestation of Holmes’s leadership created an organizational culture characterized by distinct and ultimately pathological patterns. Analysis of employee testimonials, court documents, and investigative reporting reveals how Holmes established control mechanisms that simultaneously motivated performance while preventing critical evaluation of the company’s fundamental technological claims.

Holmes implemented extreme compartmentalization within Theranos, maintaining rigid information barriers between departments and restricting employee access to company-wide knowledge. This compartmentalization exceeded typical protocols for intellectual property protection, instead functioning primarily to prevent employees from developing comprehensive understanding of Theranos’s technological limitations. For example, engineers working on hardware components were prohibited from accessing software specifications, while those developing assays had minimal visibility into the integrated functionality of the devices (Cheung, 2020). This structural fragmentation prevented collective recognition of systemic failures while enabling Holmes to maintain different narratives with different stakeholders.

Physical and electronic surveillance systems reinforced cultural control. The Theranos facility featured extensive security measures including fingerprint scanners, restricted access zones, continuous video monitoring, and tracking of electronic communications (Carreyrou, 2018). While presented externally as necessary for trade secret protection, these measures effectively constrained information flow and discouraged internal dissent. Former employees reported awareness that their communications were monitored, creating what Foucault (1977) termed “panoptic effects”—self-regulation due to potential surveillance—that discouraged questioning of company claims or practices.

Holmes cultivated intense loyalty among key executives, particularly through her relationship with Ramesh “Sunny” Balwani, who joined Theranos as Chief Operating Officer in 2009 while simultaneously maintaining an undisclosed romantic relationship with Holmes. This dual professional-personal relationship created problematic power dynamics, with Balwani serving as both operational enforcer of Holmes’s vision and emotional supporter, eliminating a potential source of critical perspective or restraint. Their leadership dyad exhibited characteristics of what Janis (1982) termed “groupthink,” where maintenance of group cohesion supersedes critical analysis or ethical consideration.

The culture manifested distinct treatment of dissent and compliance. Former employees described a pattern wherein individuals who raised concerns about technological limitations, ethical issues, or misrepresentations were marginalized, intimidated, or terminated, often accompanied by aggressive legal threats regarding confidentiality obligations (Cheung, 2020). Conversely, those who demonstrated unwavering commitment to Holmes’s vision received substantial rewards including promotions, equity, and direct validation. This differential reinforcement pattern created powerful incentives for cognitive and behavioral alignment with Holmes’s claims regardless of empirical contradictions.

Strategic Impression Management Across Stakeholder Domains

Holmes demonstrated sophisticated impression management strategies tailored to specific stakeholder domains, creating differentiated perceptions that facilitated resource acquisition while minimizing critical scrutiny. This multi-faceted impression management operated across three primary domains: media and public relations, investor relationships, and regulatory engagement.

In media interactions, Holmes leveraged narrative techniques that resonated with journalistic preferences for compelling personal stories and transformative technological narratives. She granted selected journalists carefully managed access to Theranos facilities, demonstrations, and personal interviews while maintaining strict information control through non-disclosure agreements and approval rights over content. These arrangements facilitated largely uncritical profiles in major publications including Fortune, Forbes, The New Yorker, and Inc. Magazine between 2013 and 2015, which substantially enhanced Holmes’s public legitimacy and Theranos’s perceived credibility. Furthermore, Holmes strategically employed visual presentation elements including the distinctive black turtleneck, minimal makeup, and direct eye contact to project authenticity and conviction, creating a distinctive and memorable leadership persona that increased media coverage and public recognition.

With investors, Holmes employed differentiated impression management strategies based on investor sophistication and due diligence requirements. For institutional investors with scientific expertise, Theranos limited detailed technological examination by invoking proprietary protection concerns while emphasizing future potential and first-mover advantage. For individual investors without technical backgrounds, Holmes emphasized Theranos’s expanding pharmacy partnerships, apparent regulatory approvals, and board member prestige as surrogate indicators of technological validity. Common across investor interactions was Holmes’s deployment of technical jargon with sufficient specificity to suggest deep scientific knowledge while avoiding verifiable claims that could be definitively falsified (Leary & Kowalski, 1990). Additionally, Holmes created perception of exclusivity and urgency around investment opportunities, leveraging psychological principles of scarcity to accelerate commitment while minimizing due diligence (Cialdini, 2009).

Holmes’s regulatory impression management demonstrated particular sophistication in navigating complex oversight frameworks while minimizing substantive disclosure. Theranos strategically classified its proprietary analyzer, the Edison device, under laboratory-developed test frameworks rather than medical device regulations, reducing FDA oversight requirements. When engaging with regulators, Holmes projected cooperative intentions while simultaneously employing procedural tactics including delayed responses, limited access to technology, and legal challenges that effectively postponed comprehensive regulatory evaluation. Former employees testified that Holmes directly instructed them to hide certain laboratory operations during regulatory inspections, including creating a fabricated “demonstration laboratory” that concealed the company’s actual reliance on modified third-party analyzers rather than proprietary technology (United States v. Elizabeth Holmes, 2021).

The Paradox of Authentic Deception: Psychological Dimensions

A particularly complex aspect of Holmes’s leadership concerns the psychological mechanisms that enabled persistent misrepresentation of technological capabilities despite mounting contradictory evidence. This presents what might be termed the paradox of authentic deception—Holmes simultaneously conveyed extraordinary conviction in Theranos’s capabilities while confronting significant evidence of technological failure, raising questions about self-deception, rationalization, and the psychological boundaries between deception and delusion.

Evidence suggests Holmes exhibited characteristics associated with narcissistic personality orientation in leadership contexts, including grandiose self-concept, belief in exceptional abilities, hypersensitivity to criticism, and entitled exceptionalism regarding ethical boundaries (Paulhus & Williams, 2002). These characteristics potentially facilitated cognitive distortions that reframed deception as visionary optimism and reinterpreted technological failures as temporary obstacles rather than fundamental limitations. Holmes repeatedly invoked comparisons between Theranos and historically transformative technologies that initially encountered skepticism, implying that skepticism itself validated her position rather than warranting serious consideration.

The concept of “ethical fading” (Tenbrunsel & Messick, 2004) provides insight into Holmes’s progressive normalization of deceptive practices. This process involves the gradual displacement of ethical dimensions from decision-making through reframing actions in non-moral terms. Former employees reported that Holmes consistently characterized technological failures as simply developmental challenges, reframing deceptive statements to investors or partners as “forward-looking projections” rather than misrepresentations. This linguistic and cognitive reframing facilitated ethical disengagement while maintaining self-perception as a visionary leader rather than perpetrator of fraud.

Holmes demonstrated remarkable compartmentalization capabilities, maintaining distinct representational frameworks for different audiences. With laboratory staff confronting technological failures, she acknowledged challenges while emphasizing future solutions; with investors and media, she presented these same technologies as currently operational and validated. This psychological compartmentalization enabled maintenance of contradictory realities without apparent cognitive dissonance that might otherwise constrain deceptive behavior (Festinger, 1957).

The social validation provided by Theranos’s prestigious board, prominent investors, and media coverage likely reinforced Holmes’s psychological capacity to maintain misrepresentations despite contrary evidence. Social psychological research on conformity and authority (Asch, 1956; Milgram, 1963) suggests that such high-status validation can override individual ethical judgment and factual assessment. As Holmes accumulated influential supporters, their continued endorsement potentially reinforced her belief in ultimate technological success despite current limitations, creating a form of collective delusion sustained through mutual reinforcement.

The Failure of Governance and Oversight

The Theranos case reveals systematic failures of traditional governance and oversight mechanisms, raising profound questions about their adequacy in contexts featuring charismatic leadership, emerging technologies, and information asymmetries. These failures manifested across multiple domains: board composition and function, investor due diligence processes, media scrutiny, and regulatory frameworks.

Theranos’s board composition represented a governance paradox—extraordinary collective achievement and reputation coupled with minimal relevant expertise for meaningful oversight. The board featured former Cabinet secretaries, military leaders, and distinguished statesmen but notably lacked members with specific expertise in laboratory diagnostics, medical device development, or biotechnology commercialization. This composition reflects Holmes’s strategic prioritization of reputational capital and network access over technical oversight capacity. Further, the board’s structure evolved in ways that progressively reduced its governance effectiveness, transitioning in 2013 from a traditional board of directors to a two-tiered structure with most prominent members serving on a “Board of Counselors” with advisory rather than fiduciary responsibilities (Carreyrou, 2018).

The board demonstrated insufficient engagement with fundamental technological validation, accepting Holmes’s assertions regarding capabilities without requiring independent verification or comparison to established industry benchmarks. Court testimony revealed that board members never witnessed comprehensive demonstrations of the integrated Theranos technology performing the full range of claimed tests from finger-stick blood samples (United States v. Elizabeth Holmes, 2021). This insufficient technological diligence reflects both information barriers established by Holmes and board members’ deference to Holmes’s presumed technical expertise and vision.

Investor due diligence processes demonstrated systematic failures to penetrate Theranos’s carefully constructed information barriers. Major investors committed capital without reviewing independently validated clinical data, peer-reviewed publications, or third-party technology assessments. Even sophisticated investors accepted restrictions on technological access and verification that would typically trigger enhanced scrutiny. These diligence failures reflected both the psychological impact of Holmes’s charismatic leadership and the contextualized norms of Silicon Valley investing during this period, which often prioritized vision, growth potential, and founder characteristics over traditional validation metrics (Jacoby, 2020).

Media outlets failed to apply appropriate investigative rigor when reporting on Theranos, instead largely amplifying Holmes’s narrative with minimal critical examination. This failure partially stemmed from journalists’ limited access to technical information and restricted ability to speak with current or former employees due to restrictive non-disclosure agreements. However, it also reflected broader journalistic tendencies toward uncritical celebration of technological innovation and entrepreneurial narratives, particularly those featuring demographically distinctive founders like Holmes who represented potential transformation of traditionally homogeneous technology leadership (LaFrance, 2016).

Regulatory frameworks proved insufficient for timely identification of Theranos’s technological misrepresentations. By strategically positioning its offerings under the laboratory-developed test (LDT) classification rather than as medical devices, Theranos exploited regulatory gaps between FDA and CMS oversight. Additionally, Theranos leveraged procedural mechanisms including proprietary claims, legal challenges, and strategic timing of submissions to delay comprehensive regulatory assessment until significant harm had occurred through inaccurate test results delivered to patients (Brill, 2016).

Leadership Lessons and Implications

The Holmes case offers significant insights for leadership theory and practice, particularlyregarding the paradoxical nature of traits traditionally associated with entrepreneurial success. These lessons extend beyond individual leadership pathologies to encompass organizational dynamics, governance requirements, and ecosystem responsibilities in innovation contexts.

First, the case demonstrates how characteristics commonly celebrated in entrepreneurial contexts—unwavering confidence, inspirational vision, resilience against skepticism, and narrative persuasiveness—can transition from adaptive to destructive without appropriate constraints and accountability mechanisms. Holmes’s trajectory illustrates how these qualities enabled initial resource acquisition and stakeholder commitment but ultimately facilitated sustained deception when technological reality failed to align with proclaimed vision. This suggests the need for reconceptualizing entrepreneurial leadership development to emphasize integrative capabilities that balance visionary confidence with empirical grounding, transparent communication, and ethical self-regulation.

Second, Holmes’s leadership reveals specific vulnerabilities in organizational cultures centered on revolutionary missions and charismatic authority. The combination of meaningful purpose (democratizing healthcare), appealing innovation narrative, and Holmes’s compelling persona created powerful psychological incentives for employees to suspend critical evaluation and rationalize problematic practices as necessary sacrifices for transformative impact. Organizations pursuing ambitious innovation must therefore develop structural safeguards including protected dissent channels, technological verification protocols independent of leadership influence, and ethical accountability systems specifically designed to counterbalance mission-driven rationalization of misconduct.

Third, the case demonstrates the necessity for governance evolution corresponding to organizational maturation. Theranos’s board structure and practices remained oriented toward network expansion and legitimacy enhancement rather than transitioning to appropriate oversight as the company approached commercialization and public impact. Effective governance in innovation-driven enterprises requires planned evolution of board composition, information access, and verification procedures that increase in rigor and specificity as organizations transition from conceptual to operational phases. This planned governance evolution should include predetermined accountability triggers based on funding thresholds, commercial deployment timelines, and potential risk to public welfare.

Fourth, the Theranos failure illustrates the importance of epistemic humility and intellectual honesty as foundational leadership virtues, particularly in technically complex domains with significant information asymmetries. Holmes consistently positioned herself as having comprehensive expertise across multiple specialized disciplines—microfluidics, biochemistry, engineering, medicine, regulatory frameworks, and business strategy—while rejecting input from individuals with deeper domain-specific knowledge. This pattern reveals how the modern celebration of visionary generalists can enable dangerous overreach beyond competence boundaries when not balanced by acknowledgment of limitations and structured incorporation of specialized expertise.

Finally, the case provides instructive patterns regarding early warning signs of leadership pathologies that stakeholders should recognize:

1. Information asymmetry enforcement: Unusually restrictive communication policies, extreme compartmentalization, and aggressive legal responses to legitimate requests for verification.

2. Incongruence between public claims and operational reality: Discrepancies between capabilities described to different stakeholders, particularly gaps between marketing representations and internal technical documentation.

3. Personalization of organizational identity: Excessive fusion between leader identity and organizational mission, with criticism of specific practices framed as attacks on transformative potential.

4. Pattern of discarded expertise: Departure patterns showing disproportionate loss of subject matter experts raising concerns followed by their replacement with individuals prioritizing loyalty over specific qualification.

5. Surrogate credibility substitution: Reliance on peripheral status markers (board member prestige, media coverage, venture capital validation) as substitutes for direct evidence of technological functionality or economic viability.

Conclusion: The Leadership Paradox and Systemic Reflection

The Elizabeth Holmes case transcends individual pathology, revealing systemic vulnerabilities in how contemporary institutions evaluate, celebrate, and govern entrepreneurial leadership. Holmes’s leadership effectiveness in resource acquisition and stakeholder engagement despite fundamental technological limitations demonstrates the power of narrative, identity, and selective transparency in contexts characterized by information asymmetry and complex validation requirements. The case illustrates how features of the contemporary entrepreneurial ecosystem—celebration of disruptive vision, tolerance for “fake it till you make it” approaches, preference for charismatic founders, and investment models that reward rapid scaling over verified foundations—can create environments where deceptive leadership not only survives but thrives temporarily.

The enduring value of this case study lies not in simplistic cautionary narrative but in revealing specific mechanisms through which governance systems, organizational cultures, and leadership evaluation frameworks can be reconstructed to maintain innovation potential while reducing vulnerability to deceptive practices. By understanding how Holmes navigated and exploited institutional gaps between technical validation, investment processes, media scrutiny, and regulatory oversight, stakeholders across the innovation ecosystem can develop integrated approaches to evaluation that preserve entrepreneurial flexibility while establishing appropriate boundaries of accountability and verification.

The paradox presented by Holmes—that the same qualities enabling transformative leadership can facilitate destructive deception—suggests the need for fundamental reconsideration of how leadership potential is assessed, developed, and governed, particularly in domains where technical complexity and social impact intersect. This reconsideration must extend beyond individual ethics to encompass systemic reforms in governance structures, investment protocols, and organizational design that collectively establish appropriate constraints on charismatic authority while preserving the inspiring potential of visionary leadership.

References

Asch, S. E. (1956). Studies of independence and conformity: A minority of one against a unanimous majority. Psychological Monographs, 70(9), 1-70.

Bass, B. M., & Riggio, R. E. (2006). Transformational leadership (2nd ed.). Lawrence Erlbaum Associates.

Brill, S. (2016). Hot startup Theranos has struggled with its blood-test technology. Wall Street Journal. https://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901

Brown, M. E., & Treviño, L. K. (2006). Ethical leadership: A review and future directions. The Leadership Quarterly, 17(6), 595-616.

Carreyrou, J. (2018). Bad blood: Secrets and lies in a Silicon Valley startup. Knopf.

Cheung, E. (2020). Whistleblower: My journey to Silicon Valley and fight for justice at Theranos. Penguin.

Cialdini, R. B. (2009). Influence: Science and practice (5th ed.). Pearson Education.

Conger, J. A., & Kanungo, R. N. (1998). Charismatic leadership in organizations. Sage Publications.

Festinger, L. (1957). A theory of cognitive dissonance. Stanford University Press.

Foucault, M. (1977). Discipline and punish: The birth of the prison. Vintage Books.

Goffman, E. (1959). The presentation of self in everyday life. Doubleday.

Jacoby, M. (2020). Due diligence is not a crime: The Silicon Valley paradox in the case of Elizabeth Holmes. Criminal Law Bulletin, 56(4), 698-720.

Janis, I. L. (1982). Groupthink: Psychological studies of policy decisions and fiascoes (2nd ed.). Houghton Mifflin.

LaFrance, A. (2016). How the media failed in its Theranos coverage. The Atlantic. https://www.theatlantic.com/technology/archive/2016/10/how-the-media-failed-theranos/503765/

Leary, M. R., & Kowalski, R. M. (1990). Impression management: A literature review and two-component model. Psychological Bulletin, 107(1), 34-47.

Milgram, S. (1963). Behavioral study of obedience. Journal of Abnormal and Social Psychology, 67(4), 371-378.

Paulhus, D. L., & Williams, K. M. (2002). The dark triad of personality: Narcissism, Machiavellianism, and psychopathy. Journal of Research in Personality, 36(6), 556-563.

Tenbrunsel, A. E., & Messick, D. M. (2004). Ethical fading: The role of self-deception in unethical behavior. Social Justice Research, 17(2), 223-236.

United States v. Elizabeth Holmes, No. 5:18-cr-00258-EJD (N.D. Cal. 2021).

Weber, M. (1947). The theory of social and economic organization (A. M. Henderson & T. Parsons, Trans.). Free Press.